1. Home
  2. ENTX vs PLCE Comparison

ENTX vs PLCE Comparison

Compare ENTX & PLCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.25

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Logo Children's Place Inc. (The)

PLCE

Children's Place Inc. (The)

HOLD

Current Price

$3.23

Market Cap

73.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
PLCE
Founded
2010
1969
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
62.6M
73.8M
IPO Year
2015
1997

Fundamental Metrics

Financial Performance
Metric
ENTX
PLCE
Price
$1.25
$3.23
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$9.00
$3.50
AVG Volume (30 Days)
138.7K
235.8K
Earning Date
05-14-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.48
EPS
0.07
N/A
Revenue
$42,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.41
P/E Ratio
$19.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$2.76
52 Week High
$3.22
$9.56

Technical Indicators

Market Signals
Indicator
ENTX
PLCE
Relative Strength Index (RSI) 51.94 48.32
Support Level $1.17 $2.90
Resistance Level $1.37 $3.81
Average True Range (ATR) 0.10 0.19
MACD 0.01 0.01
Stochastic Oscillator 61.67 52.04

Price Performance

Historical Comparison
ENTX
PLCE

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About PLCE Children's Place Inc. (The)

Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.

Share on Social Networks: